News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
859,143 Results
Type
Article (87320)
Company Profile (759)
Press Release (771038)
Multimedia
Podcasts (166)
Webinars (27)
Section
Business (233007)
Career Advice (4137)
Deals (39782)
Drug Delivery (133)
Drug Development (91225)
Employer Resources (202)
FDA (18264)
Job Trends (17392)
News (397281)
Policy (39913)
Tag
Academia (3003)
Academic (2)
Accelerated approval (17)
Adcomms (35)
Allergies (123)
Alliances (56979)
ALS (139)
Alzheimer's disease (1663)
Antibody-drug conjugate (ADC) (215)
Approvals (18270)
Artificial intelligence (467)
Autoimmune disease (54)
Automation (25)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (156)
Biotechnology (484)
Bladder cancer (121)
Brain cancer (47)
Breast cancer (458)
Cancer (3663)
Cardiovascular disease (323)
Career advice (3552)
Career pathing (36)
CAR-T (236)
CDC (52)
Cell therapy (644)
Cervical cancer (32)
Clinical research (75107)
Collaboration (1321)
Company closure (4)
Compensation (878)
Complete response letters (57)
COVID-19 (2946)
CRISPR (80)
C-suite (528)
Cystic fibrosis (131)
Data (4008)
Decentralized trials (2)
Denatured (59)
Depression (106)
Diabetes (439)
Diagnostics (7069)
Digital health (32)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (226)
Drug pricing (173)
Drug shortages (36)
Duchenne muscular dystrophy (190)
Earnings (98671)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (132565)
Executive appointments (964)
FDA (20585)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (12)
Funding (1178)
Gene editing (167)
Generative AI (45)
Gene therapy (511)
GLP-1 (1007)
Government (5362)
Grass and pollen (7)
Guidances (335)
Healthcare (20937)
HIV (48)
Huntington's disease (35)
IgA nephropathy (55)
Immunology and inflammation (234)
Immuno-oncology (19)
Indications (51)
Infectious disease (3173)
Inflammatory bowel disease (180)
Inflation Reduction Act (14)
Influenza (89)
Intellectual property (176)
Interviews (815)
IPO (17923)
IRA (59)
Job creations (5196)
Job search strategy (2863)
Kidney cancer (15)
Labor market (73)
Layoffs (632)
Leadership (32)
Legal (10148)
Liver cancer (91)
Longevity (12)
Lung cancer (522)
Lymphoma (252)
Machine learning (26)
Management (66)
Manufacturing (600)
MASH (127)
Medical device (14847)
Medtech (14865)
Mergers & acquisitions (22697)
Metabolic disorders (1116)
Multiple sclerosis (132)
NASH (23)
Neurodegenerative disease (201)
Neuropsychiatric disorders (55)
Neuroscience (2623)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (55)
Obesity (550)
Opinion (306)
Ovarian cancer (122)
Pain (158)
Pancreatic cancer (159)
Parkinson's disease (224)
Partnered (28)
Patents (397)
Patient recruitment (283)
Peanut (57)
People (66122)
Pharmaceutical (144)
Pharmacy benefit managers (26)
Phase I (23152)
Phase II (32620)
Phase III (24544)
Pipeline (2565)
Policy (286)
Postmarket research (3554)
Preclinical (10452)
Press Release (72)
Prostate cancer (186)
Psychedelics (51)
Radiopharmaceuticals (281)
Rare diseases (631)
Real estate (7418)
Recruiting (78)
Regulatory (27829)
Reports (64)
Research institute (2680)
Resumes & cover letters (650)
Rett syndrome (12)
RNA editing (15)
RSV (69)
Schizophrenia (123)
Series A (196)
Series B (145)
Service/supplier (30)
Sickle cell disease (78)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4316)
State (2)
Stomach cancer (17)
Supply chain (97)
Tariffs (86)
The Weekly (105)
Vaccines (1021)
Venture capital (64)
Weight loss (384)
Women's health (57)
Worklife (21)
Date
Today (135)
Last 7 days (524)
Last 30 days (2449)
Last 365 days (33739)
2025 (24682)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (79)
Alaska (7)
Arizona (299)
Arkansas (14)
Asia (50861)
Australia (8933)
California (9094)
Canada (2770)
China (861)
Colorado (385)
Connecticut (406)
Delaware (251)
Europe (116838)
Florida (1336)
Georgia (307)
Hawaii (3)
Idaho (67)
Illinois (797)
India (47)
Indiana (446)
Iowa (19)
Japan (291)
Kansas (123)
Kentucky (36)
Louisiana (20)
Maine (76)
Maryland (1233)
Massachusetts (6832)
Michigan (303)
Minnesota (550)
Mississippi (4)
Missouri (114)
Montana (33)
Nebraska (26)
Nevada (105)
New Hampshire (76)
New Jersey (2521)
New Mexico (32)
New York (2481)
North Carolina (1378)
North Dakota (10)
Northern California (4059)
Ohio (285)
Oklahoma (19)
Oregon (50)
Pennsylvania (1893)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (45)
South Dakota (1)
Southern California (3473)
Tennessee (146)
Texas (1419)
United States (33705)
Utah (270)
Virginia (240)
Washington D.C. (82)
Washington State (783)
West Virginia (4)
Wisconsin (94)
Wyoming (1)
There are 859,143 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug pricing
Pfizer To Offer Drugs at a Discount in Agreement with US Government
Pfizer CEO Albert Bourla directly credited the threat of tariffs with leading to the deal, in which the company will offer drugs on a soon-to-be-launched website called TrumpRx.
September 30, 2025
·
2 min read
·
Dan Samorodnitsky
Government
FDA Delays Likely as Federal Government Hurtles Toward Shutdown
The agency estimates that about 86% of staff can remain in the event that funding stops, but new drug applications cannot be accepted.
September 30, 2025
·
2 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH ELEMENT
Webinar: Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
In this discussion, our guests give their observations and recommendations on how companies can navigate within the United States market and beyond. Watch now.
September 30, 2025
·
1 min read
·
BioSpace Insights
Layoffs
Sutro Makes Deeper Cuts To Extend Runway Into 2027, Reach Key Data Readout
After parting with 50% of its employees earlier this year, Sutro Biopharma will lay another third of its staff in a restructuring effort geared toward reaching key inflection points.
September 30, 2025
·
1 min read
·
Dan Samorodnitsky
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a deal centered heavily on the investigational GLP-1 drug.
September 30, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Biogen Upends 20 Employees After Axing AAV Work
Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
September 30, 2025
·
207 min read
·
BioSpace Editorial Staff
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
Despite tolerability concerns, nomlabofusp’s overall efficacy represents a “large win” for Larimar, according to analysts at William Blair, who lauded the therapy’s functional benefits.
September 30, 2025
·
2 min read
·
Tristan Manalac
Series A
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Already approved in Japan, China and other Asian countries, Crystalys’ dotinurad works to lower serum uric acid levels.
September 30, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints
Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, companies have not conducted post-approval studies “to demonstrate a benefit on hard clinical endpoints.”
September 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Merakris Therapeutics Secures FDA Agreement for Type C Meeting to Advance MTX-001 Development Pathway
September 30, 2025
·
4 min read
1 of 85,915
Next
